1-10 of 10
Matthias Klinger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Matthias Klinger, PhD, Gerhard Zugmaier, MD, Virginie Naegele, PhD, Mariele Goebeler, MD, Christian Brandl, MS, Ralf C Bargou, MD, Peter Kufer, MD
Journal: Blood
Blood (2016) 128 (22): 1589.
https://doi.org/10.1182/blood.V128.22.1589.1589
Published: 2016
Journal Articles

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Clinical Trials & Observations
Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz-A. Horst, Reinhard Marks, Christoph Faul, Helmut Diedrich, Albrecht Reichle, Monika Brüggemann, Chris Holland, Margit Schmidt, Hermann Einsele, Ralf C. Bargou, Max S. Topp
Journal: Blood
Blood (2015) 126 (24): 2578–2584.
https://doi.org/10.1182/blood-2015-06-649111
Published: 2015
Includes: Supplemental data
Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Brief Report
Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Evelyn Degenhard, Marie-Elisabeth Goebeler, Matthias Klinger, Svenja A. Neumann, Heinz A. Horst, Thorsten Raff, Andreas Viardot, Matthias Stelljes, Markus Schaich, Rudolf Köhne-Volland, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Patrick A. Baeuerle, Dirk Nagorsen, Margit Schmidt, Hermann Einsele, Gert Riethmüller, Michael Kneba, Dieter Hoelzer, Peter Kufer, Ralf C. Bargou
Journal: Blood
Blood (2012) 120 (26): 5185–5187.
https://doi.org/10.1182/blood-2012-07-441030
Published: 2012
Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Clinical Trials & Observations
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer
Journal: Blood
Blood (2012) 119 (26): 6226–6233.
https://doi.org/10.1182/blood-2012-01-400515
Published: 2012
Includes: Supplemental data
Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Max S Topp, Gerhard Zugmaier, MD, Nicola Goekbuget, MD, Svenja Neumann, MD, Heinz-August Horst, MD, Thorsten Raff, MD, Monika Brueggemann, MD, Michael Kneba, MD, Andreas Viardot, MD, Mathias Schmid, MD, Markus Schaich, MD, Matthias Stelljes, MD, Mariele Goebeler, MD, Heike Pfeiffer, MD, Oliver Ottmann, MD, Thomas Burmeister, MD, Evelyn Degenhard, Margit Schmidt, PhD, Jürgen Scheele, MD, PhD, Hermann Einsele, MD, Peter Kufer, MD, Matthias Klinger, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 174.
https://doi.org/10.1182/blood.V116.21.174.174
Published: 2010
Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD
Journal: Blood
Blood (2010) 116 (21): 2880.
https://doi.org/10.1182/blood.V116.21.2880.2880
Published: 2010
Journal Articles

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Gerhard Zugmaier, Dirk Nagorsen, Matthias Klinger, Ralf C Bargou, Mariele Goebeler, Andreas Viardot, Patrick A Baeuerle, Peter Kufer
Journal: Blood
Blood (2009) 114 (22): 4793.
https://doi.org/10.1182/blood.V114.22.4793.4793
Published: 2009
Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 4798.
https://doi.org/10.1182/blood.V114.22.4798.4798
Published: 2009
Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Max S Topp, Gerhard Zugmaier, Nicola Goekbuget, Peter Kufer, Mariele Goebeler, Matthias Klinger, Evelyn Degenhard, Patrick A Baeuerle, Margit Schmidt, Dirk Nagorsen, Svenja Neumann, Heinz A Horst, Thorsten Raff, Andreas Viardot, Matthias Stelljes, Mathias Schmid, Oliver G. Ottmann, Thomas Burmeister, Hermann Einsele, Gert Riethmueller, Dieter Hoelzer, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 840.
https://doi.org/10.1182/blood.V114.22.840.840
Published: 2009
Journal Articles

T Cell Responses during Long-Term Continuous Infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in Patients with Relapsed B-NHL: Data from Dose-Escalation Study MT103-104.

Matthias Klinger, Peter Kufer, MD, Petra Kirchinger, Ralf Lutterbüse, PhD, Eugen Leo, MD, Carsten Reinhardt, MD, Patrick Bäuerle, PhD, Ralf Bargou, MD
Journal: Blood
Blood (2006) 108 (11): 2725.
https://doi.org/10.1182/blood.V108.11.2725.2725
Published: 2006